SNY

Sanofi Healthcare - Pharmaceuticals Investor Relations →

NO
7.3% ABOVE
↑ Moving away Was 4.4% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $45.10
14-Week RSI 65
Rel. Volume (14w) This week's trading vs. the 14-week average 1.1x
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 1.53 — Buyers winning

Sanofi (SNY) closed at $48.37 as of 2026-11-13, trading 7.3% above its 200-week moving average of $45.10. The stock moved further from the line this week, up from 4.4% last week. The 14-week RSI sits at 65, indicating neutral momentum.

Over the past 14 weeks, up-weeks have carried more volume than down-weeks (1.53 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.

Over the past 1223 weeks of data, SNY has crossed below its 200-week moving average 20 times. On average, these episodes lasted 14 weeks. Historically, investors who bought SNY at the start of these episodes saw an average one-year return of +10.3%.

With a market cap of $116.1 billion, SNY is a large-cap stock. The company generates a free cash flow yield of 7.1%, which is healthy. Return on equity stands at 5.7%. The stock trades at 1.4x book value.

Over the past 23.5 years, a hypothetical investment of $100 in SNY would have grown to $387, compared to $1180 for the S&P 500. SNY has returned 5.9% annualized vs 11.1% for the index, underperforming the broader market over this period.

Free cash flow has been declining at a -5% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: SNY vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After SNY Crosses Below the Line?

Across 20 historical episodes, buying SNY when it crossed below its 200-week moving average produced an average return of +7.4% after 12 months (median +13.0%), compared to +13.6% for the S&P 500 over the same periods. 75% of those episodes were profitable after one year. After 24 months, the average return was +22.1% vs +34.5% for the index.

Each line shows $100 invested at the moment SNY crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Bean Score Experimental

The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices SNY would reach each dislocation threshold.

Current Bean Score -2.52σ
Current FCF Yield 7.25%
Baseline Yield 8.79%
Historical σ 0.52pp

Dislocation Price Levels

Prices where SNY's Bean Score would hit each σ threshold. Valid until next earnings report: 2027-01-28.

LevelσPriceSignal
Deep Value+2σ$36.61Unusually cheap — analysis point
Value+1σ$38.69Cheap vs. own history
Fair Value+0σ$41.03Historical mean behavior
Expensive-1σ$43.66Expensive vs. own history
Deep Expensive-2σ$46.65Unusually expensive — analysis point

Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end

Recent Earnings

DateEPS Est.EPS ActualSurprise
2026-10-30$1.51$1.98+31.2%
2026-07-30$1.14$1.20+5.6%
2026-04-23$1.03$1.10+7.3%
2026-01-29$0.85$0.91+7.4%
Data depth: 2 quarterly baselines, 19 price observations — Limited history (4+ quarters preferred for reliability)

Signal Accuracy Collecting Data

The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"

21 / 13 weeks minimum

the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral

Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.

Dislocation Scores Experimental

Each score measures deviation from SNY's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation +0.01σ Dividend yield vs own 10-yr norm
Drawdown Score +0.26σ Distance from line vs own history
Sector-Relative +0.92σ Vs sector median this week
Buyback Acceleration -2.3pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -5.2pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+4.0pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

SNY has crossed below its 200-week MA 20 times with an average 1-year return of +10.3% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Jul 2003Sep 200356.3%+21.2%+318.0%
Jan 2008Sep 20098635.7%-21.7%+165.4%
Feb 2010Feb 201011.4%+2.1%+174.8%
Apr 2010Sep 20102113.9%+22.2%+186.1%
Nov 2010Jan 201172.4%+3.5%+188.0%
Nov 2015Mar 20177115.8%-0.5%+76.7%
Apr 2017Apr 201710.8%-6.4%+65.4%
Dec 2017Jan 201841.6%+5.6%+63.3%
Jan 2018Jul 20182210.6%+5.2%+63.3%
Mar 2020Mar 202017.2%+36.2%+69.7%
Aug 2022Nov 20221514.9%+25.2%+30.0%
Oct 2023Nov 202337.0%+31.3%+28.9%
Dec 2023Dec 202310.3%+9.1%+20.0%
Feb 2024Feb 202421.7%+19.6%+19.5%
Apr 2024Apr 202422.6%+16.9%+21.0%
Sep 2025Sep 202511.3%-4.7%+12.1%
Jan 2026Jan 202610.1%N/A+9.6%
Feb 2026Feb 202611.4%N/A+11.0%
Mar 2026Mar 202636.6%N/A+14.6%
Apr 2026Nov 20262711.3%N/A+10.8%
Average14—+10.3%—

Frequently Asked Questions

Is SNY below its 200-week moving average?

No. Sanofi (SNY) is currently 7.3% above its 200-week moving average of $45.10. It would need to fall to $45.10 to cross below the line.

What is SNY's 200-week moving average price?

Sanofi's 200-week moving average is $45.10 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when SNY drops below its 200-week moving average?

SNY has crossed below its 200-week moving average 20 times in our data. On average, buying at that moment produced a one-year return of +10.3%. These dips have historically been decent entry points. These episodes lasted 14 weeks on average.

Is SNY a good value right now?

Here's what our data says about SNY as of 2026-11-13: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 65. Free cash flow yield is 7.1%. Return on equity is 5.7%. Price-to-book is 1.4x. This is not a buy or sell recommendation — always do your own research.

How does SNY compare to the S&P 500?

Over the past 23.5 years, $100 invested in SNY would have grown to $387, compared to $1180 for the S&P 500. That's 5.9% annualized vs 11.1% for the index. SNY has underperformed the broader market over this period.

Does SNY pay a dividend?

Yes. Sanofi currently pays a dividend yield of 500.00%.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13